Literature DB >> 16412706

Early rise of anti-pseudomonas antibodies and a mucoid phenotype of pseudomonas aeruginosa are risk factors for development of chronic lung infection--a case control study.

Tacjana Pressler1, Birgitte Frederiksen, Marianne Skov, Peter Garred, Christian Koch, Niels Høiby.   

Abstract

P. aeruginosa is the most significant pathogen in CF lung disease. Chronic infection is preceded by a period of intermittent colonization. Early aggressive antimicrobial treatment at initial detection of P. aeruginosa in lower respiratory tract (LRT) secretions can prevent transition to chronic infection in approximately 80% of the patients, while the rest progress to chronic infection in spite of treatment. To analyze risk factors for development of chronic infection, a cohort of 89 CF patients free of chronic infection at the study period start was followed for 10 years. 28 of the patients (study group) developed chronic infection in spite of early treatment and 28 age-matched patients who did not (controls) were included in the analysis. During the 3 years period prior to onset of chronic infection, P. aeruginosa-positive cultures were more frequent in the study group than in the controls (2.2 vs. 0.5 per year, p<0.0001). Growth of mucoid strains of P. aeruginosa was more frequent in study group than in controls (11.5% vs. 0%, p<0.0001). Most important, specific anti-pseudomonal IgG serum antibodies were significantly higher in the study group than in controls (0.98 Elisa Units vs. 0.53, p=0.04) already 3 years prior to onset of chronic infection and increased 0.44 EU pr year in the study group but remained at the initial level in the control group (p<0.005). Occurrence of Aspergillus-positive cultures were significantly more frequent in the study group than in controls (p=0.01). The strongest risk factor for development of chronic P. aeruginosa infection was increasing levels of specific anti-pseudomonal antibodies, specifically of IgG1 and IgG4 subclass and total anti-Pseudomonas IgG, 3 years prior to onset of chronic infection, with odds ratio (OR) 8.9, 7.7 and 7.4, respectively (p<0.005), and growth of mucoid P. aeruginosa strains with OR of 7.4, p=0.006). Occurrence of Aspergillus was also a risk factor for developing chronic P. aeruginosa infection with the OR of 4.7 (p=0.008).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16412706     DOI: 10.1016/j.jcf.2005.11.002

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  21 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 2.  Virulence attenuating combination therapy: a potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients.

Authors:  Elana Shaw; William M Wuest
Journal:  RSC Med Chem       Date:  2020-02-19

3.  Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study.

Authors:  Matthew R Crull; Ranjani Somayaji; Kathleen J Ramos; Ellen Caldwell; Nicole Mayer-Hamblett; Moira L Aitken; David P Nichols; Ali Rowhani-Rahbar; Christopher H Goss
Journal:  Clin Infect Dis       Date:  2018-09-14       Impact factor: 9.079

4.  Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.

Authors:  Margaret Rosenfeld; Julia Emerson; Sharon McNamara; Valeria Thompson; Bonnie W Ramsey; Wayne Morgan; Ronald L Gibson
Journal:  J Cyst Fibros       Date:  2012-05-01       Impact factor: 5.482

5.  Sinus biofilms in patients with cystic fibrosis: is adjusted eradication therapy needed?

Authors:  Kasper Aanaes; Steffen Eickhardt; Helle Krogh Johansen; Christian von Buchwald; Marianne Skov; Niels Høiby; Thomas Bjarnsholt
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-09       Impact factor: 2.503

Review 6.  Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  Bridget Stuart; Jenny H Lin; Peter J Mogayzel
Journal:  Paediatr Respir Rev       Date:  2010-06-16       Impact factor: 2.726

7.  Immunoproteomics to examine cystic fibrosis host interactions with extracellular Pseudomonas aeruginosa proteins.

Authors:  Hamish G Upritchard; Stuart J Cordwell; Iain L Lamont
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

8.  Secretory IgA-mediated immune response in saliva and early detection of Pseudomonas aeruginosa in the lower airways of pediatric cystic fibrosis patients.

Authors:  Renan Marrichi Mauch; Claudio Lucio Rossi; Marcos Tadeu Nolasco da Silva; Talita Bianchi Aiello; José Dirceu Ribeiro; Antônio Fernando Ribeiro; Niels Høiby; Carlos Emilio Levy
Journal:  Med Microbiol Immunol       Date:  2019-01-31       Impact factor: 3.402

9.  Comparison of culture and qPCR for the detection of Pseudomonas aeruginosa in not chronically infected cystic fibrosis patients.

Authors:  Pieter Deschaght; Petra Schelstraete; Guido Lopes dos Santos Santiago; Leen Van Simaey; Filomeen Haerynck; Sabine Van Daele; Elke De Wachter; Anne Malfroot; Patrick Lebecque; Christiane Knoop; Georges Casimir; Hedwige Boboli; Frédéric Pierart; Kristine Desager; Mario Vaneechoutte; Frans De Baets
Journal:  BMC Microbiol       Date:  2010-09-24       Impact factor: 3.605

10.  Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium.

Authors:  Jose A G Ferreira; John C Penner; Richard B Moss; Janus A J Haagensen; Karl V Clemons; Alfred M Spormann; Hasan Nazik; Kevin Cohen; Niaz Banaei; Elisabete Carolino; David A Stevens
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.